Biotest Valuation
Is BIO3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIO3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIO3 (€27.2) is trading below our estimate of fair value (€97.19)
Significantly Below Fair Value: BIO3 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIO3?
Key metric: As BIO3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BIO3's PE Ratio? | |
|---|---|
| PE Ratio | 15.8x |
| Earnings | €68.50m |
| Market Cap | €1.36b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.8x |
| Enterprise Value/EBITDA | 19.5x |
| PEG Ratio | 0.5x |
Price to Earnings Ratio vs Peers
How does BIO3's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 53.4x | ||
688276 Changchun BCHT Biotechnology | 25.9x | 40.7% | CN¥10.7b |
MDXG MiMedx Group | 16.8x | -1.9% | US$1.4b |
300685 Amoy Diagnostics | 31.4x | 19.6% | CN¥9.9b |
GNS Genus | 139.7x | 37.7% | UK£1.1b |
BIO3 Biotest | 15.8x | 29.3% | €1.4b |
Price-To-Earnings vs Peers: BIO3 is good value based on its Price-To-Earnings Ratio (15.8x) compared to the peer average (53.5x).
Price to Earnings Ratio vs Industry
How does BIO3's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: BIO3 is good value based on its Price-To-Earnings Ratio (15.8x) compared to the European Biotechs industry average (27x).
Price to Earnings Ratio vs Fair Ratio
What is BIO3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIO3's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
ALM
€8.40
7D
-0.1%
1Y
0.3%
Teva Pharmaceutical Industries
US$19.4b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$16.30
7D
5.5%
1Y
80.7%
Merck KGaA
€61.6b
Operates as a science and technology company in Germany.
MRCK
€141.45
7D
1.1%
1Y
-11.5%